Breakthrough Victoria and Monash University Invest $2.25M in Three Medical Startups Targeting Rare Disease and Autoimmune Conditions
核心洞察
Breakthrough Victoria (搜索) and Monash University have co-invested $2.25 million in three medical startups through the newly launched Monash Ventures Pre-Seed Fund.
The funded companies include Myostellar (搜索) developing biologic therapy (搜索) for Duchenne Muscular Dystrophy (搜索), FytonBio (搜索) creating antibody therapies (搜索) for autoimmune diseases (搜索), and Remagine Labs (搜索) designing wearable drug delivery devices.
The investment is part of Breakthrough Victoria (搜索)'s $100 million University Innovation Platform, which has committed over $480 million across 36 companies and is forecast to contribute $5.3 billion to Victoria's economy by 2035.
Breakthrough Victoria (搜索) and Monash University have jointly invested $2.25 million in three emerging medical startups developing innovative therapies for rare diseases and chronic conditions (搜索). The funding comes through the newly launched Monash Ventures Pre-Seed Fund, a $15 million initiative designed to commercialize breakthrough medical technologies that could reduce pressure on Victoria's health system.
The three companies receiving investment represent diverse approaches to addressing unmet medical needs. Myostellar (搜索) is developing a biologic therapy (搜索) to treat Duchenne Muscular Dystrophy (搜索) by promoting muscle regeneration while limiting fibrosis. FytonBio (搜索) focuses on next-generation antibody therapies (搜索) for autoimmune diseases (搜索), while Remagine Labs (搜索) is creating wearable drug delivery devices to improve treatment for chronic conditions (搜索).
Strategic Investment Framework
The funding forms part of Breakthrough Victoria (搜索)'s $100 million University Innovation Platform, which aims to commercialize research from seven Victorian universities. The Monash Ventures Pre-Seed Fund investment committee, comprising representatives from Monash University, Breakthrough Victoria, and independent members, has assessed 13 startups and endorsed 10 for investment to date.
"These investments are a powerful demonstration of how the University Innovation Platform is working exactly as intended — backing world-class research at its earliest stages to successfully commercialize and deliver real-world solutions," said Breakthrough Victoria (搜索) CEO Rod Bristow.
Company Development Programs
Chuck Silberstein, CEO and co-founder of FytonBio (搜索), explained that the funding enables the company to begin antibody discovery for its first therapeutic program. "It marks an exciting step forward in our mission to deliver potential functional cures in autoimmunity and inflammation by deleting pathogenic immune cells," he said.
Remagine Labs (搜索) CEO Pat Kelly emphasized the significance of the investment for their electro-pharmaceutical development. "Their investment is a powerful endorsement of our technology and our commitment to building a globally competitive electro-pharmaceutical company here in Victoria," Kelly stated.
Professor Peter Currie, co-founder of Myostellar (搜索), highlighted the importance of institutional support in the commercialization process. "While we progress the research, I cannot emphasize enough the importance of finding someone who's been on the commercialization journey before," he said. "I was fortunate to find this within my institution and am incredibly grateful to Monash Innovation for their invaluable guidance."
Economic Impact and Future Outlook
The investment marks the formal introduction of Monash Ventures, a new venture identity reflecting Monash University's increasing role as an active investor in innovation. Professor Sharon Pickering, Vice-Chancellor and President of Monash University, said the initiative represents "a bold step in strengthening our impact through innovation and enterprise."
Breakthrough Victoria (搜索) has committed more than $480 million across 36 companies and six funds to date, helping facilitate nearly $1.3 billion in co-investment. An independent report by EY found that these efforts are forecast to deliver up to $5.3 billion in economic impact for Victoria by 2035.
Victorian Minister for Economic Growth and Jobs Danny Pearson welcomed the announcement, stating: "We are backing world-class research because it generates lifesaving treatments and drives our economy. These investments help industries and businesses to grow, so more Victorians have secure jobs they can count on."